MNOV vs. PVLA, AARD, TVRD, TNXP, CADL, IMMP, ACB, SLRN, CGC, and TVGN
Should you be buying MediciNova stock or one of its competitors? The main competitors of MediciNova include Palvella Therapeutics (PVLA), Aardvark Therapeutics (AARD), Tvardi Therapeutics (TVRD), Tonix Pharmaceuticals (TNXP), Candel Therapeutics (CADL), Prima BioMed (IMMP), Aurora Cannabis (ACB), Acelyrin (SLRN), Canopy Growth (CGC), and Semper Paratus Acquisition (TVGN). These companies are all part of the "pharmaceutical products" industry.
MediciNova vs. Its Competitors
Palvella Therapeutics (NASDAQ:PVLA) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.
MediciNova has lower revenue, but higher earnings than Palvella Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.
Palvella Therapeutics currently has a consensus target price of $46.29, suggesting a potential upside of 94.23%. MediciNova has a consensus target price of $7.00, suggesting a potential upside of 451.18%. Given MediciNova's stronger consensus rating and higher possible upside, analysts plainly believe MediciNova is more favorable than Palvella Therapeutics.
Palvella Therapeutics has a beta of -0.11, indicating that its stock price is 111% less volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.
40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 20.5% of Palvella Therapeutics shares are held by insiders. Comparatively, 13.6% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Palvella Therapeutics had 4 more articles in the media than MediciNova. MarketBeat recorded 5 mentions for Palvella Therapeutics and 1 mentions for MediciNova. MediciNova's average media sentiment score of 0.93 beat Palvella Therapeutics' score of 0.93 indicating that MediciNova is being referred to more favorably in the news media.
MediciNova's return on equity of -20.77% beat Palvella Therapeutics' return on equity.
Summary
MediciNova beats Palvella Therapeutics on 9 of the 15 factors compared between the two stocks.
Get MediciNova News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MNOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MediciNova Competitors List
Related Companies and Tools
This page (NASDAQ:MNOV) was last updated on 7/3/2025 by MarketBeat.com Staff
Free MNOV Stock Alerts